BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is now trading -15.40% off 52-week high price. On the other end, the stock has been noted 34.72% away from the low price over the last 52-weeks. The stock changed 0.59% to recent value of $84.71. The stock transacted 912986 shares during last trading day however it has an average volume of 1.41M shares. The company has 179.71M of outstanding shares and 178.75M shares were floated in the market.
On Jan. 8, 2020, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 at 8:45am ET in New York. To access the live webcast,
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company’s portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
Its earnings per share (EPS) expected to touch remained -1.80% for this year. BMRN has a gross margin of 78.90% and an operating margin of -8.10% while its profit margin remained -2.70% for the last 12 months.
According to the most recent quarter its current ratio was 3.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of 1.46% from the mean of 20 days, 6.79% from mean of 50 days SMA and performed 6.34% from mean of 200 days price. Company’s performance for the week was 0.19%, 5.99% for month and YTD performance remained 0.19%.